DE69309906T2 - Behandlung für entzündungserkrankung des darmes - Google Patents

Behandlung für entzündungserkrankung des darmes

Info

Publication number
DE69309906T2
DE69309906T2 DE69309906T DE69309906T DE69309906T2 DE 69309906 T2 DE69309906 T2 DE 69309906T2 DE 69309906 T DE69309906 T DE 69309906T DE 69309906 T DE69309906 T DE 69309906T DE 69309906 T2 DE69309906 T2 DE 69309906T2
Authority
DE
Germany
Prior art keywords
treatment
inflammatory diseases
tissus
ibd
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69309906T
Other languages
English (en)
Other versions
DE69309906D1 (de
Inventor
Roy Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25268692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69309906(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of DE69309906D1 publication Critical patent/DE69309906D1/de
Application granted granted Critical
Publication of DE69309906T2 publication Critical patent/DE69309906T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69309906T 1992-02-12 1993-02-02 Behandlung für entzündungserkrankung des darmes Revoked DE69309906T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83513992A 1992-02-12 1992-02-12
PCT/US1993/000924 WO1993015764A1 (en) 1992-02-12 1993-02-02 Treatment for inflammatory bowel disease

Publications (2)

Publication Number Publication Date
DE69309906D1 DE69309906D1 (de) 1997-05-22
DE69309906T2 true DE69309906T2 (de) 1997-11-06

Family

ID=25268692

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69309906T Revoked DE69309906T2 (de) 1992-02-12 1993-02-02 Behandlung für entzündungserkrankung des darmes

Country Status (11)

Country Link
EP (1) EP0625912B1 (de)
JP (3) JPH07506566A (de)
AT (1) ATE151642T1 (de)
AU (1) AU674302B2 (de)
CA (1) CA2129637C (de)
DE (1) DE69309906T2 (de)
DK (1) DK0625912T3 (de)
ES (1) ES2103468T3 (de)
GR (1) GR3024041T3 (de)
HK (1) HK1007683A1 (de)
WO (1) WO1993015764A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
CA2148712C (en) 1992-11-13 2012-01-17 Thalia Papayannopoulou Peripheralization of hematopoietic stem cells
EP0682529B2 (de) * 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antikörper zur behandlung von insulinabhängigem diabetes
AU727187B2 (en) * 1993-02-09 2000-12-07 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
ZA947006B (en) * 1993-09-15 1995-05-02 Univ Emory Method of inhibiting binding of reticulocytes to endothelium by interfering with vla-4/vcam-1 interactions
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP1759709B1 (de) * 1994-01-25 2013-02-27 Elan Pharmaceuticals Inc. Humanisierte Antikörper gegen das Leukozytenadhäsionsmolekül VLA-4
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
PT1113810E (pt) 1998-09-14 2009-03-10 Univ Texas Processos de tratamento de mieloma múltiplo e reabsorção óssea induzida por mieloma utilizando antagonistas da ligação do receptor de integrina
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
WO2003070709A1 (fr) 2002-02-20 2003-08-28 Ajinomoto Co.,Inc. Nouveau derive de phenylalanine
MY157727A (en) 2002-02-25 2016-07-15 Biogen Idec Inc Administration of agents for the treatment of inflamation
AU2004303696B2 (en) 2003-12-22 2011-03-31 Ea Pharma Co., Ltd. Novel phenylalanine derivative
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP4652356B2 (ja) 2007-02-26 2011-03-16 アルプス電気株式会社 ターンシグナルスイッチ装置
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
DK3466977T3 (en) 2010-04-16 2022-04-11 Biogen Ma Inc Anti-vla-4-antistoffer
LT2704742T (lt) 2011-05-02 2017-10-25 Millennium Pharmaceuticals, Inc. Anti-alfa4beta7 antikūno kompozicija
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN109884295B (zh) * 2017-12-25 2022-03-08 苏州和锐生物科技有限公司 假单胞菌多肽、抗体捕获器件及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852374T2 (de) * 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
US5147637A (en) * 1988-06-07 1992-09-15 The Rockefeller University Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma
DK162890D0 (da) 1990-07-06 1990-07-06 Novo Nordisk As Polypeptid
WO1993006864A1 (en) * 1991-10-01 1993-04-15 The General Hospital Corporation Preventing allograft rejection with antibodies to adhesion molecules

Also Published As

Publication number Publication date
CA2129637A1 (en) 1993-08-19
AU3605993A (en) 1993-09-03
JP2007045843A (ja) 2007-02-22
JPH07506566A (ja) 1995-07-20
HK1007683A1 (en) 1999-04-23
CA2129637C (en) 1999-05-04
DK0625912T3 (da) 1997-10-27
DE69309906D1 (de) 1997-05-22
ES2103468T3 (es) 1997-09-16
AU674302B2 (en) 1996-12-19
ATE151642T1 (de) 1997-05-15
GR3024041T3 (en) 1997-10-31
JP2004002472A (ja) 2004-01-08
EP0625912B1 (de) 1997-04-16
JP4108572B2 (ja) 2008-06-25
WO1993015764A1 (en) 1993-08-19
EP0625912A1 (de) 1994-11-30

Similar Documents

Publication Publication Date Title
DE69309906D1 (de) Behandlung für entzündungserkrankung des darmes
DE69636327D1 (de) System zum sammeln von blut ohne es zu beschädigen
DK1014996T3 (da) Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
BR9712488A (pt) Anticorpo anti-hm 1.24 humano remodelado
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
ES2094733T3 (es) Deteccion de enfermedades o disfunciones neurologicas.
ATE150319T1 (de) Behandlung von asthma
DE3855525D1 (de) Verwendung eines Protein gebundenen Polysaccharid Zur Herstellung eines Arzneimittels für die Behandlung von AIDS.
ATE194497T1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
CA2034881A1 (en) Factor x-laci hybrid protein
EP0937982A3 (de) Diagnostikum und Therapeutikum zur Behandlung der autoimmunen Hepatitis
FR2658197B1 (fr) Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
SE8904007D0 (sv) Monoklona antikroppar och diagnostiseringsmetod
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
MX9206339A (es) Nueva proteina inhibidora de trombina a partir de chinches de monte
FR2618439B1 (fr) Sequences d'amino-acides reproduisant au moins en partie la sequence des lectines animales et humaines, leurs procedes d'obtention, leurs applications diagnostiques et therapeutiques
ES2049021T3 (es) Metodo de recuperar la proteina epi purificada a partir de una solucion, especialmente una solucion de fermentacion.
DE69529405T2 (de) Pd-ecgf / thymidin phosphorylase spezifischer monoklonaler antikörper
SE8600987L (sv) Forfarande for framstellning av ett protein- koncentrat ur helblod
MX9700413A (es) Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso.
RU96109171A (ru) Способ идентификации тела погибшего
DE69023500D1 (de) Verfahren zum nachweis von antikörpern gegen streptokinase.
RU93004826A (ru) Способ мездрения кож и шкур
UA15941A (uk) Спосіб діагhостики початкових стадій гіпертоhічhої хвороби

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation